Metastatic Breast Cancer Clinical Trials in Detroit, Michigan

5 studies are recruiting for metastatic breast cancer in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

   This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hor…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   79 in total

   Run by

   BioNTech SE

   See if you can join NCT06827236 on ClinicalTrials.gov

2. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

3. A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

   The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBio…

   Stage

   Not phased

   Ages

   22 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   8 in total

   Run by

   Barbara Ann Karmanos Cancer Institute

   See if you can join NCT07227831 on ClinicalTrials.gov

4. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

   This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford Hospital, Detroit, Michigan

   Locations

   192 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05894239 on ClinicalTrials.gov

5. Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

   The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Hospital, Detroit, Michigan

   Locations

   14 in total

   Run by

   Ellipses Pharma

   See if you can join NCT05573126 on ClinicalTrials.gov